Kazia has added two further indications to the development program for its brain-penetrant PI3K inhibitor GDC-0084 through collaborations with prestigious US-based cancer centers. The collaborations further validate the potential of GDC-0084, which was in-licensed from Genentech in 2016. Importantly, the two additional indications will provide alternative pathways to a potential first marketing approval for GDC-0084, increasing the overall likelihood of success. Kazia’s ongoing Phase II
29 Oct 2018
Kazia Therapeutics - New indications for GDC-0084
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kazia Therapeutics - New indications for GDC-0084
- Published:
29 Oct 2018 -
Author:
Dr Dennis Hulme -
Pages:
9
Kazia has added two further indications to the development program for its brain-penetrant PI3K inhibitor GDC-0084 through collaborations with prestigious US-based cancer centers. The collaborations further validate the potential of GDC-0084, which was in-licensed from Genentech in 2016. Importantly, the two additional indications will provide alternative pathways to a potential first marketing approval for GDC-0084, increasing the overall likelihood of success. Kazia’s ongoing Phase II